Sanofi Stock: Will This Be a Big Pharma Winner in 2014?
Shares of Sanofi trailed the broader market last year as the company suffered an FDA rejection of its multiple sclerosis drug Lemtrada, and saw revenue fall due to patent expirations. However, CEO Chris Viehbacher recently stated in a recent CNBC interview that the company's pipeline is one of the top five in the big pharma industry.
Is he right, or overly optimistic?
Motley Fool analyst Max Macaluso examines this statement and Sanofi's overall business in the following video. He focuses on the key factors that could see the company return to growth this year, and Sanofi's unique strategy to avoid another patent cliff.
Biotech stocks are known for volatility. What's the best way to play this space?
The best way to play the biotech space is to find companies that shun the status quo and, instead, discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report, "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.
The article Sanofi Stock: Will This Be a Big Pharma Winner in 2014? originally appeared on Fool.com.Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.